Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.

Slides:



Advertisements
Similar presentations
Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Advertisements

With Dr. Mark Wainberg (moderator) and
Immune-Based Interventions for HIV Infection and AIDS Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University Medical.
Comparison of Effects of Atazanavir, Raltegravir or Darunavir with FTC/Tenofovir on Biomarkers of Systemic Inflammation, Macrophage and T-Cell Activation:
Grace A McComsey, Douglas Kitch, Paul E Sax, Camlin Tierney, Nasreen C Jahed, Kathleen Melbourne, Belinda Ha, Todd T Brown, Anthony Bloom, Neal Fedarko,
Inflammation biomarkers in HIV infection Laurence WEISS.
Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Immunopathogenesis of AIDS, an historical perspective: Or 30 years in 15 minutes Michael M. Lederman, MD.
Immunosenescence - Results of BELFRAIL (and INCIVAR) By Adriaensen Wim Department of Public Health and Primary Care, KU Leuven & UCL, Belgium.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Suzanne Crowe Associate Director, Burnet Institute
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
Cryptococcal IRIS: Pathogenesis & Pearls for Clinical Management
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Toronto I-II 4:00 pm The end of AIDS: HIV as a chronic inflammatory disease Steven Deeks Professor of medicine in residence at the University of California,
Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha,
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
CCR5 antagonists to prevent IRIS: Rationale, design and update of a blinded multicenter study in progress (CADIRIS) J Sierra-Madero, I.Sanne,L.Azzoni,
Myeloid cells matter Conclusions. Glut1+ CD14++ CD16+ Associated with inflammatory markers HIV Immune activation HIV-related diseases Joshua Anzigen:
1 Depletion of naïve CD4+T cell compartment by immune hyperactivation can be rapidly reversed by AntiViral- HyperActivation Limiting Therapeutics (AV-HALTs)
HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Peter W. Hunt, MD Associate Professor of Medicine in Residence
HIV Infection and Accelerated Aging Why is this happening? What can be done to prevent or reverse the process? Steven G. Deeks, MD Professor of Medicine.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Introductory talk D Costagliola.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
What drives persistent immune activation/inflammation in cART-treated HIV-1? Giulia Marchetti, MD, PhD Dept of Health Sciences, Clinic of Infectious Diseases.
Kimberly Dunbar, PA-S2 Follow-up of Cardiovascular Risk Markers in Hypertensive Patients Treated with Irbesartan: Results of the i-SEARCH Plus Registry.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
Regulatory T cell abnormalities associated with aberrant CD4+ T-cell responses in HIV+ patients with immune reconstitution disease (IRD) Nabila SEDDIKI.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health.
Cardiovascular Complications of HIV and Its Treatment
Immune activation & Inflammation in HIV infection
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Slide 1 of 44 From SG Weibel, MD, at San Francisco, CA: May 6, 2016, IAS-USA. Getting Hotter As We Get Older Sara Gianella Weibel, MD Assistant Professor.
E. Turner Overton, MD Associate Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama Statins, Rainwater, and Pure Grain Alcohol:
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division.
Immune Ageing and Viral Co-Factors
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
HIV and Aging: A Paradigm Shift in the Management of HIV Disease
The role of unknown risk factors in coronary heart disease
Inflammation Markers and The Risk of Non-AIDS Events
HIV and Inflammation Jihad Slim, MD June 2016.
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept 
The Impact of Aging on People Living with HIV
Residual Disease and Immune Activation/Inflammation on ART
When to START During an OI
Presentation transcript:

Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division

A shift in focus… T cell activation as a target for interventions in the pre-ART era Monocyte activation and inflammation a target during treated HIV disease Why this shift is occurring –Important caveats Implications for future clinical trials

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency MS Gottlieb, R Schroff, HM Schanker, JD Weisman, PT Fan, RA Wolf, and A Saxon Dec 10, 1981 T10=CD38 Leu3=CD4

CD8+ T cell activation predicts survival better than VL in patients with AIDS (CD4<200) Janice Giorgi Giorgi, JID, 1999 (see also: Giorgi, JAIDS, 2002) Survival P=0.02 Survival P=0.001

T Cell Activation Declines with ART Hunt et al, JID, 2003; PLoS One, 2011

But Remains Abnormally High During ART-mediated Viral Suppresion Hunt et al, JID, 2003; PLoS One, 2011

Is T cell activation a cause of disease in treated HIV infection or simply a marker for some other process? Important for identifying targets for novel interventions

Low CD4 Count during ART Predicts non-AIDS Death Young et al for COHERE cohort, PLoS Med, 2012 (see also Baker, AIDS, 2008)

IL-2 Increases CD4 Counts in Treated Patients Abrams et al, NEJM, 2009 IL-2 also decreases HLA-DR and CD38 expression (Kovacs, NEJM, 1995)

However, IL-2 Had No Effect on AIDS/Death Abrams et al, NEJM, 2009 P=0.47 P=0.55 CD4 count (and CD38 / DR expression) is not 100% specific for the pathophysiologic pathway mediating disease.

Why didn’t IL-2 work? May have expanded the wrong type of CD4+ T cells (regulatory cells). –Impaired functional immune responses? Could CD4+ T cell count just be a marker for some other immunologic process?

What Specific Immunologic Pathways are Driving Disease during ART? Non-AIDS Morbidity / Mortality Innate Immune Activation (MØ/DC) CD4 Lymphopenia Inflammation T and B Cell Activation/ Dysfunction ? ? ? Coagulation ?

What Specific Immunologic Pathways are Driving Disease during ART? Non-AIDS Morbidity / Mortality Innate Immune Activation (MØ/DC) CD4 Lymphopenia Inflammation T and B Cell Activation/ Dysfunction ? ? ? Coagulation ?

Hunt et al, JID, 2003 (see also Goicoechea, JID, 2006; Gandhi, JAIDS, 2006) High T Cell Activation Associated with Blunted CD4 Recovery during ART

Lederman et al., JID, 2011 Inflammation and Innate Immune Activation are Increased in Patients with Poor CD4+ T cell Recovery on ART IL-6 sCD14 CD4<350 CD4>500 HIV- CD4<350 CD4>500 HIV-

How do we get a better sense of the specific immunlogic pathways driving disease?

Eden et al., JID, 2007 (see also: Burdo, AIDS, 2013; Lyons, JAIDS, 2011; Letendre, CROI 2012, Abstract #82) Abnormal CSF Neopterin Levels Persist Despite 4 Years of VL Suppression 60% Abnormal

Sinclair, JAIDS, 2008 CD8+ T Cell Activation is Not Persistently Elevated in CSF During Suppressive ART T cell activation in the CNS is unlikely to explain persistent neurocognitive dysfunction in ART-suppressed individuals

Baker, CROI 2013, Abstract #66LB Monocyte Activation Predicts Coronary Artery Calcium Progression: SUN Study T cell Activation Not Predictive

Do these markers predict clinical events?

SMART: Inflammatory Markers Strongly Associated with Mortality and CVD Events Biomarker All-Cause Mortality (N=85) Fatal or Non-fatal CVD (N=136) ORP-valueORP-value hs-CRP IL-612.4< Amyloid A Amyloid P D-dimer41.2< F Kuller L et al. PLoS Med, 2008; Duprez, Atherosclerosis, 2009 Even after adjusting for CD4 count!

Hunt, CROI 2012, Abstr #278 (see also : Tenorio, CROI 2013, Abstr# 790) Innate Immune Activation Predicts Mortality More Strongly than T Cell Activation: SOCA Gut Epithelial Barrier Dysfunction Inflammation / Coagulation Matched for age, gender, duration VL suppression, CMV retinitis, nadir CD4 IDO-1 Induction Monocyte Activation

Hunt, CROI 2012, Abstr #278 (see also : Tenorio, CROI 2013, Abstr# 790) Innate Markers Predict Mortality Independent of Nadir AND Current CD4 count Gut Epithelial Barrier Dysfunction Inflammation / Coagulation Also adjusted for current CD4 count IDO-1 Induction Monocyte Activation Current CD4 count no longer predictive of mortality after adjusting for innate markers

Why does T cell “senescence” not predict mortality in HIV infection?

Lee, CROI 2013, #294

HIV Disease Drives Expansion of CD28- CD8+ T Cells... All CMV+ Lee, CROI 2013, #309 P= P=0.10

But CD57 is inappropriately low on CD28- CD8+ T Cells in HIV infection All CMV+ Lee, CROI 2013, #309 P< P=0.0003

Low (Not High) CD57 on CD28- CD8+ T Cells Predicts Mortality in Treated HIV *Subjects matched on age, gender, duration of viral suppression, presence of CMV retinitis, and nadir CD4+ cell count Lee, CROI 2013, #309

Higher Monocyte Activation Associated with the Low CD57 CD8+ T cell Defect Lee, CROI 2013, #309 Monocyte activation may cause T cell proliferative defects in HIV by: PD1-driven IL-10 release (Said, Nat Med, 2010) IDO-1 induction (Boasso, Blood, 2007)

What Specific Immunologic Pathways are Driving Disease during ART? Non-AIDS Morbidity / Mortality Innate Immune Activation (MØ/DC) CD4 Lymphopenia Inflammation T and B Cell Activation/ Dysfunction ? ? Coagulation

Caveats…

T / B Cell Activation Predicts NHL (MACS) Breen, Cancer Epi Bio, 2011 Adjusted for age, duration HIV infection, and CD4 count

T Cell Activation may be an important contributor to HIV reservoir size… Hatano, JID, 2013

Implications for Clinical Trials

CD8 Activation is a Reproducible and Responsive Marker Hunt, Blood, 2013 Placebo Arm Std Dev of ∆ Wk 0-24: 0.13 log 10 % ~35% relative change

Lots of Within-subject Variability in IL-6 Std Dev of ∆ Wk 0-24: 0.38 log 10 pg/ml ~2.4-fold relative change Hunt, Blood, 2013

sCD14 is much better, comparable variability to T cell activation Std Dev of ∆ Wk 0-24: 0.11 log 10 ug/ml ~29% relative change Hunt, Blood, 2013

Several immunologic defects predict disease in treated HIV infection: –Innate immune activation and inflammation –CD4 lymphopenia –T cell / B bell activation and dysfunction Innate immune activation and inflammation independently predict disease, less consistent for other markers. Interventions designed to decrease activation of myeloid lineage cells may hold promise. –Statins, ASA? –Microbial Translocation interventions –Treating co-infections? Summary

Acknowledgements NIAID Jason Brenchley Danny Douek Irini Sereti Core Immunology Lab/DEM Elizabeth Sinclair Lorrie Epling Mike McCune SOCA Curtis Meinert Mark Van Natta ACTG Heather Ribaudo SCOPE/OPTIONS/UCSF Sulggi Lee Steve Deeks Jeff Martin Hiroyu Hatano Vivek Jain Rebecca Hoh Rick Hecht CWRU Wei Jiang Michael Lederman Nick Funderburg Brian Claggett U Minnesota Jason Baker R56AI100765, 1R21AI087035, 1R21AI07877, DDCF CSDA